Cambridge, MA · Founded 2018 · Privately Held (backing)
Operator of a biotechnology company intended to develop breakthrough glycol-therapeutics for patients. Aviceda Therapeutics is based in Cambridge, MA and was founded in 2018. It was valued at $347 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $276 million across 3 recorded rounds; the latest was a $75 million later-stage round in Nov 2024.
PMV mark · valuation
$346.5M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$276.3M
Last round
Later Stage VC
Nov 2024
Cap table — not yet on record
Aviceda Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Aviceda Therapeutics with a free account
·The complete investor list: 13 names
·Watch Aviceda Therapeutics: the Monday email on marks, rounds and moves
Where does Aviceda Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Aviceda Therapeutics's 3 recorded funding rounds.
